Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Efficacy and safety of elbasvir/grazoprevir in participants with HCV genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study.

Wei L, Jia JD, Wang FS, Niu JQ, Zhao XM, Mu S, Liang LW, Wang Z, Hwang P, Robertson MN, Ingravallo P, Asante-Appiah E, Wei B, Evans B, Hanna GJ, Talwani R, Duan ZP, Zhdanov K, Cheng PN, Tanwandee T, Nguyen VK, Heo J, Isakov V, George J; C-CORAL Investigators.

J Gastroenterol Hepatol. 2018 Oct 12. doi: 10.1111/jgh.14509. [Epub ahead of print]

PMID:
30311701
2.

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD.

Oral Oncol. 2018 Oct;85:29-34. doi: 10.1016/j.oraloncology.2018.08.005. Epub 2018 Aug 17.

PMID:
30220316
3.

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE.

JCI Insight. 2018 Sep 6;3(17). pii: 122799. doi: 10.1172/jci.insight.122799. [Epub ahead of print]

4.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group.

Clin Infect Dis. 2018 Aug 31. doi: 10.1093/cid/ciy540. [Epub ahead of print]

PMID:
30184165
5.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

PMID:
30150660
6.

Human papillomavirus and oropharyngeal cancer.

Villa A, Hanna GJ.

Curr Probl Cancer. 2018 Jun 27. pii: S0147-0272(18)30107-7. doi: 10.1016/j.currproblcancer.2018.06.005. [Epub ahead of print] Review. No abstract available.

PMID:
30049422
7.

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.

Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP.

Ann Oncol. 2018 Sep 1;29(9):1980-1986. doi: 10.1093/annonc/mdy251.

PMID:
30010779
8.

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.

PMID:
29960819
9.

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.

Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ.

Oral Oncol. 2018 Jun;81:1-9. doi: 10.1016/j.oraloncology.2018.04.007. Epub 2018 Apr 10.

PMID:
29884406
10.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.

Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W; ONCEMRK Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):589-598. doi: 10.1097/QAI.0000000000001723.

11.

CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies.

Schaefer IM, Dal Cin P, Landry LM, Fletcher CDM, Hanna GJ, French CA.

Genes Chromosomes Cancer. 2018 Sep;57(9):446-451. doi: 10.1002/gcc.3. Epub 2018 Aug 14.

PMID:
29700887
12.

Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.

Zamor PJ, Vierling J, Ghalib R, Luketic V, Ravendhran N, Balart L, Robertson M, Hwang P, Hanna GJ, Nguyen BY, Barr E, Talwani R, Pearlman B.

Am J Gastroenterol. 2018 Jun;113(6):863-871. doi: 10.1038/s41395-018-0053-4. Epub 2018 Apr 26.

PMID:
29695828
13.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
14.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. [Epub ahead of print]

15.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

PMID:
29301825
16.

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.

Lataillade M, Zhou N, Joshi SR, Lee S, Stock DA, Hanna GJ, Krystal M; AI438011 study team.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):299-307. doi: 10.1097/QAI.0000000000001602.

17.

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H.

Oncologist. 2017 Nov;22(11):1413. doi: 10.1634/theoncologist.2016-0298erratum. No abstract available.

18.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

PMID:
29101162
19.

Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH.

Int J Oral Maxillofac Surg. 2018 May;47(5):568-577. doi: 10.1016/j.ijom.2017.09.006. Epub 2017 Sep 29.

PMID:
28969885
20.

Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.

Hanna GJ, Adkins DR, Zolkind P, Uppaluri R.

Oral Oncol. 2017 Oct;73:65-69. doi: 10.1016/j.oraloncology.2017.08.008. Epub 2017 Aug 17. Review.

PMID:
28939078

Supplemental Content

Loading ...
Support Center